KOSDAQBiotech & Pharma114450

Green Lifescience

₩1,961▲ 1.82%2026-11-18 close
Market Cap
₩39.2B
Turnover
₩68,775,518
Volume
40K
Shares out.
20M
PER
7.9×
PBR
0.9×
EPS
₩266
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

AI Chip Materials Expand, Affiliate Dependence Remains the Test

Green Lifescience is shifting from pharmaceutical intermediates toward AI chip materials, and revenue has risen for four straight quarters, but its reliance on related party Green Chemical remains high.

  1. 1

    On a disclosed basis, revenue rose from KRW 36.5 billion in 2022 to KRW 40.3 billion in 2025, with growth in both 2024 and 2025.

  2. 2

    Operating profit turned positive at KRW 377 million in 2024, but fell 45.8% to KRW 204 million in 2025, leaving an operating margin of 0.5%.

  3. 3

    Quarterly revenue has risen for four consecutive quarters through the third quarter of 2026, reaching KRW 20.5 billion, up 81.1% year on year, but the same quarter showed a KRW 1.6 billion net loss attributable to controlling shareholders.

  4. 4

    A large share of sales goes to Green Chemical, with its share reported at 68.83% in the first quarter of 2026.

  5. 5

    Two AI chip materials supply contracts, worth KRW 14.03 billion and KRW 10.05 billion, were disclosed in 2026, and both run through December 31, 2026, making follow-on contracts the key item to watch.

02

Business structure

Green Lifescience produces and sells pharmaceutical raw materials and intermediates alongside fine chemical materials. The business is split into an electronic materials segment and a pharmaceutical intermediates segment.

According to IB Tomato reporting, electronic materials sales were KRW 22 billion in 2025 on a full-year basis, versus KRW 6.6 billion for pharmaceutical intermediates.

The electronic materials segment centers on AI chip materials and raw materials for electronic circuit boards, and according to a financial information summary, supply of AI chip materials began in the fourth quarter of 2025. The company is also reported to be developing peptide intermediates for GLP-1 class drugs.

The customer base is concentrated in a few parties. Sales to Green Chemical rose from 21.51 percent of revenue in 2024 to 50.65 percent in 2025, and were reported at 68.83 percent in the first quarter of 2026.

IB Tomato reporting published in August 2026 said the top two customers accounted for 81.64 percent of sales, with customer A at 63.83 percent. Utilization at the Hwachi plant was reported to have risen from 62 percent in 2025 to 80 percent in the first quarter of 2026.

In pharmaceutical intermediates the company competes with many API and fine chemical producers, while electronic materials compete with domestic materials suppliers.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩11.4B₩100M0.9%
2025Q4₩12.6B₩1.2B9.7%
2026Q1₩15.5B₩600M3.8%
2026Q2₩19B₩1.8B9.5%
2026Q3₩20.5B₩1.6B7.6%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩36.5B-₩4B-₩3.5B−10.8%−6.7%18.6%
2023₩22.4B-₩4.6B-₩16.4B−20.8%−45.5%21.9%
2024₩24.9B₩400M₩1.6B1.5%4.4%25.8%
2025₩40.3B₩200M₩100M0.5%0.3%43.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

Annual revenue fell from KRW 36.5 billion in 2022 to KRW 22.4 billion in 2023, a 38.7% decline, then rose 11.1% to KRW 24.9 billion in 2024 and 62.3% to KRW 40.3 billion in 2025, marking two straight years of growth. 2025 was the largest year of 2022 to 2025 and 2023 was the smallest.

Operating losses of KRW 3.96 billion in 2022 and KRW 4.64 billion in 2023 were followed by an operating profit of KRW 377 million in 2024, a turn to profit.

The company attributed the 2024 turn to lower depreciation after an earlier impairment of tangible assets and to cost reduction efforts, according to Edaily reporting.

Operating profit fell 45.8% to KRW 204 million in 2025, and the company said sales rose on its entry into AI chip materials while operating profit declined on higher raw material prices, according to Edaily.

Operating margin was -10.8 percent in 2022, -20.8 percent in 2023, 1.5 percent in 2024 and 0.5 percent in 2025, so margins stayed thin even as sales grew. Net profit attributable to controlling shareholders swung to KRW 1.56 billion in 2024 and then fell 92.9% to KRW 110 million in 2025.

By quarter, operating profit was KRW 105 million in the third quarter of 2025, KRW 1.22 billion in the fourth quarter, KRW 585 million in the first quarter of 2026 (down 52.1 percent from the prior quarter), KRW 1.8 billion in the second quarter and KRW 1.57 billion in the third quarter.

Net profit attributable to controlling shareholders of KRW 4.38 billion in the second quarter of 2026 far exceeded operating profit, while the third quarter showed a net loss of KRW 1.6 billion attributable to controlling shareholders.

With operating profit positive in the same quarter, the composition of non-operating items matters. Operating cash flow in the first quarter of 2026 was reported at negative KRW 256 million, according to Green Economy Daily based on the quarterly report.

The debt ratio rose from 18.6 percent in 2022 to 43.3 percent in 2025, with total equity of KRW 38.3 billion and total liabilities of KRW 16.6 billion at the end of 2025.

05

Industry analysis

Green Lifescience faces two end markets. One is electronic materials used in semiconductor and display industries, including AI chip materials, raw materials for electronic circuit boards and fine chemicals for QLED materials. The other is pharmaceutical raw materials and intermediates.

The company has said it is widening its fine chemicals business in response to growth in semiconductor and display industries, according to IB Tomato reporting. AI chip materials are cited as a fast-growing market, but the company's demand leans heavily on contracts with affiliates such as Green Chemical.

On the pharmaceutical side, rising global demand for APIs was cited as the rationale for capacity expansion.

Peers in the same biopharma sector, such as Samsung Biologics and Celltrion, rely on large production capacity and long-term supply contracts, while Green Lifescience centers on intermediates and fine chemical materials, so its business model differs.

Its revenue scale is far smaller than the large biopharma companies, and its customer base is concentrated in a few parties. Indicators used to gauge where the business sits in its industry cycle include plant utilization and the pace of supply contract renewals.

The first-quarter 2026 recovery in utilization was explained by lower fixed cost burden per unit. Whether the utilization level holds after the current contracts end is not yet clear.

Materials businesses are sensitive to raw material price swings, so how raw material costs flow into future margins is another point to track.

06

Outlook

Two AI chip materials supply contracts were disclosed in 2026. The contract disclosed on March 17, 2026 is worth KRW 14.03 billion and runs through December 31, 2026. The contract disclosed on May 13, 2026 is worth KRW 10.05 billion and runs from May 18 to December 31, 2026. The counterparty for both is Green Chemical.

The company said contract amounts and periods may change through discussions with customers and that contract volumes and amounts are fixed based on purchase orders, according to CBC News reporting.

On capacity, the company disclosed a new facility investment of KRW 6.5 billion and plans to complete the expansion by year end to raise production capacity a step higher, according to IB Tomato reporting. The investment aims to expand AI chip materials production and add new API products.

The company said it is working to diversify its customers and that orders are coming in heavily but capacity has been insufficient to meet demand, according to IB Tomato. No commercial production timing has been disclosed for the GLP-1 peptide intermediates under development.

Following the pattern of the prior year, the fourth-quarter 2026 provisional results are expected around late January 2027. With both contracts ending in late 2026, revenue structure after 2027 depends on follow-on contracts and progress in diversifying the customer base.

Whether the new capacity turns into stable profit is tied to continued supply to the leading customers. The announced schedule places completion of the expansion at the end of 2026.

07

Valuation

PER
7.9×
PBR
0.9×
ROE
13.4%
EPS
₩266
BPS
₩2,356
Dividend per share
₩0

Valuation can be read through two lenses, earnings scale and net assets. Net profit attributable to controlling shareholders over the last four quarters totals KRW 5.26 billion, a small base, so earnings multiples are sensitive to quarterly swings.

The third-quarter 2026 net loss attributable to controlling shareholders remains a factor in that four-quarter total. The price-to-book ratio sits below 1x, and total equity of KRW 38.3 billion at the end of 2025 is entirely attributable to controlling shareholders.

Because losses were recorded in 2022 and 2023, the profit track record usable for earnings-based comparison is short, starting from 2024. The dividend yield is below the industry average. The debt ratio rise from 18.6 percent in 2022 to 43.3 percent in 2025 is also part of the balance sheet burden.

Because earnings have moved sharply, how multiples read will depend on whether operating profit and net profit attributable to controlling shareholders move in the same direction in the next annual report.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Four Straight Quarters of Revenue Growth

Revenue rose for four consecutive quarters, from KRW 11.4 billion in the third quarter of 2025 to KRW 20.5 billion in the third quarter of 2026, with third-quarter sales up 81.1 percent year on year.

Operating profit stayed positive, at KRW 1.22 billion in the fourth quarter of 2025, KRW 1.8 billion in the second quarter of 2026 and KRW 1.57 billion in the third quarter. Growth in both sales and profit is cited as the core bullish argument.

Utilization Recovery and Expansion Plan

Reports say utilization at the Hwachi plant rose from 62 percent in 2025 to 80 percent in the first quarter of 2026. The company disclosed a new facility investment of KRW 6.5 billion and plans to complete the expansion by year end. Lower fixed cost per unit is cited as a benefit. The company also says orders have exceeded what its capacity can handle.

AI Chip Materials and New API Pipeline

Two AI chip materials supply contracts, worth KRW 14.03 billion and KRW 10.05 billion, were disclosed in 2026. The company supplies raw materials for electronic circuit boards to domestic customers and is reportedly developing GLP-1 class peptide intermediates.

As the business expands from pharmaceutical intermediates into electronic materials, sales mix diversification is becoming visible.

09

Bear factors

Rising Dependence on an Affiliate

Sales to Green Chemical rose from 21.51 percent of revenue in 2024 to 50.65 percent in 2025 and 68.83 percent in the first quarter of 2026. Reports also say the top two customers accounted for 81.64 percent of sales.

Because both recent contracts are with Green Chemical, revenue continuity after contract expiry is seen as the main weakness. The company says it is working to diversify customers.

Quarterly Earnings Swings and Cash Flow

Net profit attributable to controlling shareholders swung from KRW 4.38 billion in the second quarter of 2026 to a net loss of KRW 1.6 billion in the third quarter, even though operating profit stayed positive at KRW 1.57 billion.

Operating cash flow in the first quarter of 2026 was reported at negative KRW 256 million. Sharp swings in quarterly earnings and quarters without cash generation are cited as bearish factors.

Cost Pressure and Financial Headroom

The company attributed the 45.8 percent fall in 2025 operating profit to higher raw material prices. The operating margin was just 0.5 percent in 2025, leaving a thin cushion relative to sales. The debt ratio rose from 18.6 percent in 2022 to 43.3 percent in 2025. If raw material costs keep rising, earnings strength could weaken quickly even with operating profit positive.

10

Risk factors

Customer Concentration

Reports say the top two customers account for 81.64 percent of sales. If orders from a specific customer fall or contracts are not renewed, utilization and revenue could both be affected. With both current contracts ending in late 2026, whether follow-on contracts are signed is the most direct risk.

Discrepancies in Related Party Disclosures

According to Green Economy Daily, the first-quarter 2026 report recorded KRW 10.7 billion in sales to Green Chemical, while Green Chemical reported purchases of KRW 4.49 billion, a gap of about KRW 6.2 billion. A similar gap appeared in the 2025 annual report. Consistency of related party transaction records is a point to check in the next periodic reports.

Contract Terms Can Change

The company has said that the amount and period of its AI chip materials supply contracts may change through discussions with customers. Contract amounts are counted at the point the purchase order is fixed. How much of the disclosed contract value turns into actual revenue, and when, depends on order execution.

11

What to watch next

  1. December 31, 2026

    The contract periods of the two AI chip materials supply agreements with Green Chemical, disclosed in March and May 2026, end. Whether follow-on contracts are disclosed and their size will indicate revenue continuity.

  2. Late December 2026

    This is the target completion point for the KRW 6.5 billion facility investment at the Hwachi plant. Whether the expansion is completed on schedule and how utilization changes will show whether AI chip materials and API production growth is being delivered.

  3. Around late January 2027

    The fourth-quarter 2026 provisional results are expected around this period, following the late January release pattern of the prior year. The checkpoints are whether operating profit and net profit attributable to controlling shareholders move in the same direction and whether the four-quarter revenue growth streak continues.

  4. Around late March 2027

    The 2026 annual business report is normally due at the end of March. Annual operating margin, debt ratio, operating cash flow and the affiliate sales share will be fixed on a disclosed basis.

12

Overall view

Green Lifescience is moving from a pharmaceutical intermediates base toward AI chip materials and electronic materials. Its 2025 revenue of KRW 40.3 billion was the largest of 2022 to 2025, and revenue has risen for four straight quarters through the third quarter of 2026.

Operating profit has stayed positive on a quarterly basis in 2026. On the other hand, annual operating profit fell to KRW 204 million in 2025, leaving a 0.5 percent margin. Because much of the sales depends on Green Chemical, the period after both supply contracts end in late 2026 is a key inflection point.

The net loss attributable to controlling shareholders in the third quarter of 2026, the negative operating cash flow in the first quarter and the discrepancies in related party records are factors that call for checking earnings quality. Capacity expansion and the utilization recovery are bullish production factors.

The next checkpoints are year-end contract renewals, the fourth-quarter 2026 provisional results and the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. goinsider.kr
  2. newstomato.com
  3. newstomato.com
  4. comp.fnguide.com
  5. ibtomato.com
  6. greened.kr
  7. businessreport.kr
  8. etnews.com
  9. cbci.co.kr
  10. hankyung.com
  11. topstarnews.net
  12. edaily.co.kr
  13. sedaily.com
  14. edaily.co.kr
  15. edaily.co.kr
  16. plus.hankyung.com
  17. m.news.nate.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis